Opinion
Video
Author(s):
Medical experts discuss the LAUNCH study, EMERALD-1, and LEAP-012 trials, providing updates on the progress and findings that influence the treatment paradigm for hepatocellular carcinoma.
Rivoceranib Plus Camrelizumab Maintains Frontline Survival Benefit in Unresectable HCC
Breast Cancer Experts Share Obstacles and Successes as Women in Oncology
N-803/BCG Approval Signals Paradigm Shift in Management of BCG-Unresponsive NMIBC
FDA Approval Insights: NALIRIFOX in Metastatic Pancreatic Cancer
ASCO Updates Advanced HCC Treatment Guideline
Personalized Dosimetry With Y-90 Glass Microspheres Shows Positive Activity in HCC
Dr Grünwald on Examining Progression Patterns for Lenvatinib Plus Pembrolizumab in Advanced RCC
Dr Gerds on Updated Data for Pelabresib Plus Ruxolitinib in JAK Inhibitior–Naive Myelofibrosis
Asciminib Bests Standard-of-Care TKIs in Ph+ CML
Lorlatinib Yields Longest Reported PFS in Advanced ALK+ NSCLC